UBAMATAMAB + Ubletamig + SARILUMAB

2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

UBAMATAMAB + Ubletamig + SARILUMAB
Treatment and conditionWhere it standsTrials
UBAMATAMAB + Ubletamig + SARILUMAB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBAMATAMAB + Ubletamig + SARILUMAB for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1